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Poster Session I S2730.005 one sided) but not at 1 year (p 5 0.34, two-sided). There was
no significant difference in mortality rates between the EAP group
and the control group.
Conclusions: Multiple transfusions raise the risk of secondary he-
mochromatosis, a risk factor for infections and increased mortality.
Erythropoietin-assisted phlebotomy is a treatment to prevent the
complications of iron overload in HSCT patients.328
SAFETY AND IMMUNOGENICITY OF HEAT-TREATED ZOSTER VACCINE
(ZVHT) IN ADULTS WITH ALLOGENEIC OR AUTOLOGOUS HEMATOPOI-
ETIC STEM-CELL TRANSPLANTS (HCT)
Winston, D.1, Mullane, K.2, Boeckh, M.3, Zhao, Y.4, Fernsler, D.4,
Manoff, S.4, Annunziato, P.4 1University of California - Los Angeles;
2University of Chicago; 3Fred Hutchinson Cancer Research Center;
4Merck & Co., Inc
Background: Herpes zoster incidence is higher in patients with
a hematopoietic stem cell transplant [HCT] (200 cases/1000 per-
son-years) than in the general population (3-5 cases/1000 per-
son-years). A heat-treated zoster vaccine [ZVHT] was assessed in
adults with allogeneic or autologous HCT.
Methods: Randomized, double-blind, placebo-controlled, multi-
center Phase I study of a 4-dose ZVHT regimen (1 dose pre-HCT;
3 doses post-HCT, each 30 days apart) in adults $ 18 years with
autologous (n 5 50) or allogeneic (n 5 50) HCT. In each group,
40 received ZVHT and 10 placebo (Pbo). Bloodwas collected at base-
line & 28 days after each dose to measure (1) VZV antibody con-
centrations by glycoprotein enzyme-linked immunosorbent assay
(gpELISA), and (2) varicella zoster virus (VZV) T-cell responses
by interferon-gamma enzyme-linked immunospot (IFN-g ELI-
SPOT) assay. All vaccinated patients were evaluated for adverse
events (AEs) through day 28 postdose 4. Immunogenicity analyses
for both HCT groups were exploratory (no pre-specified hypothe-
ses).
Results: ZVHT safety profile was similar to placebo. Injection-site
adverse events (AEs) occurred in 15% of the ZVHT group and
10% of the Pbo group. There were no reported vaccine-related
serious AEs. No patients discontinued due to vaccine-related AEs.
Herpes zoster (PCR positive) occurred in 1 ZVHT and 1 placebo pa-
tient (both autologous HCT patients). There were also 2 patients in
the ZVHT group that had suspected HZ not confirmed by PCR (1 inTable 1. Immunogenicity Results Summary
Allogeneic HCT Autologous HCT
ZVHT Placebo ZVHT Placebo
[N540] [N510] [N540] [N510]
[n] Response
(90%CI)
[n] Response
(90%CI)
[n] Response
(90%CI)
[n] Response
(90%CI)
Day 1 (baseline)
GMC [28] 13.7 (6.6,28.4) [7] 4 (0.7,22.2) [31] 9.1 (5.2,15.9) [7] 8.6 (2,8,26.1)
Postdose 1
GMC [29] 2.2 (1.1,4.2) [9] 1.1 (0.5,5.5) [24] 10.8 (5.3,22.3) [7] 4.3 (1.7,10.9)
GMFR [20] 0.1 (0.0,0.3) [7] 0.2 (0.1,1.0) [20] 0.4 (0.2,0.9) [7] 0.5 (0.1,2.1)
Postdose 2
GMC [27] 2.6 (1.5,4.4) [8] 1.1 (0.7,1.7) [25] 12.6 (5.6,28.4) [5] 4.8 (0.5,50.0)
GMFR [20] 0.2 (0.2,0.4) [6] 0.4 (0.1,1.8) [18] 0.6 (0.3,1.2) [3] 1.2 (0.0,287.4)
Postdose 3
GMC [22] 2.1 (1.0,4.3) [7] 0.9 (0.6,1.4) [27] 63.3 (33.0,121.3) [5] 2.0 (0.4,9.6)
GMFR [14] 0.1 (0.0,0.5) [6] 0.3 (0.1,1.8) [21] 4.5 (1.7,11.7) [3] 0.1 (0.0,2.5)
Postdose 4
GMC [26] 2.7 (1.5,4.9) [5] 0.5 (0.5,0.5) [24] 92.2 (47.0,180.9) [5] 4.9 (0.8,30.5)
GMFR [17] 0.2 (0.1,0.5) [4] 0.2 (0.0,7.8) [19] 7.6 (2.7,21.7) [4] 0.5 (0.1, 4.7)
N5number of patients vaccinated.
n5number of patients included in analysis.
GMC5geometric mean count.
GMFR5geometric mean fold rise from Day1 (baseline).eachHCT group). No ZVHT recipient had a rash that was PCR pos-
itive for the vaccine strain of VZV.
At baseline, the VZV-specific gpELISA geometric mean titer
(GMT) was 152 (90% CI: 107, 216) in allogenic HCT patients
and 214 (90%CI: 147, 311) in autologous HCT patients. Both mea-
sures decreased Postdose 4: 139 (90% CI: 103, 189) and 196 (90%
CI: 126, 305), respectively. VZV-IFN- g responses are summarized
in the table below.
Conclusion: 4 doses of ZVHT had an acceptable safety profile in pa-
tients undergoingHCT. Significant T-cell responses were elicited in
patients undergoing autologous HCT, but not in patients undergo-
ing allogeneic HCT.
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INCREASED RESTING ENERGY EXPENDITURE IS ASSOCIATED WITH
FAILURE TO THRIVE IN SEVERE COMBINED IMMUNODEFICIENCY
Makhija, M., Barron, M.A., Hagen, L.E.M., Pencharz, P.,
Grunebaum, E., Roifman, C. The Hospital for Sick Children, Toronto,
ON, Canada
Introduction: Patients with Severe Combined Immunodeficiency
(SCID) often suffer from failure to thrive (FTT) caused by chronic
infections, poor energy intake and/or malabsorption. Increased rest-
ing energy expenditure (REE)might also contribute to FTT in these
patients as it does in patients with other immune deficient states in-
cluding HIV and malignancy.
Objectives:Our objectives were to measure REE (MREE) and de-
termine if increased REE (hypermetabolism) is associated with
FTT in SCID patients at diagnosis prior to bone marrow trans-
plantation.
Study Design: REE was measured by indirect calorimetry in 26 pa-
tients with SCID, before BMT conditioning, at a single transplant
center. Predicted REE (PREE) was determined byWHO standards.
MREE. 110% of PREE was classified as hypermetabolism. Other
data collected at diagnosis included FTT status, infectious history,
genotype, phenotype and the feeding methods used.
Results: Fifteen of 26 (57.7%) patients were FTT and 18/26 (69.2%)
were hypermetabolic. Hypermetabolism occurred in 14/15 (93%) pa-
tients with FTT, while only 4/11 (36%) patients without FTThad hy-
permetabolism (P5 0.003).Therewas a significant difference between
the MREE (455 6 169 kcal) and the PREE (333 6 106 kcal) (p\
0.0001). Hypermetabolism was significantly more common in those
between the ages of 3-12 months. Logistic regression was performed
to determine the probability of FTT using the MREE expressed as
a percentage of the PREE for age and gender, adjusted for diarrhea
and pneumonia. An increased probability of FTT was found, if hyper-
metabolism was present, independent of diarrhea and pneumonia.
Eleven of 17 (65%) patients required nasogastric feeding and/or paren-
teral nutrition to meet their energy needs.
Conclusions: Hypermetabolism is common in patients with SCID
in the pre-BMT period and may contribute to the development of
FTT. The hypermetabolism in these patients may necessitate inten-
sive nutrition support.
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EXPERIENCE WITH CMX001, A NOVEL ANTIVIRAL DRUG, FOR CYTO-
MEGALOVIRUS INFECTIONS IN STEM CELL TRANSPLANT PATIENTS
Papanicolau, G.1, Kurtzberg, J.2, Westervelt, P.3, Gea-Banacloche, J.4,
Warlick, E.5, Lanier, R.6, Anderson, M.6, Painter, W.6 1Memorial Sloan
Kettering Cancer Center, New York, NY; 2Duke UniversityMedical Cen-
ter, Durham, NC; 3Washington University School of Medicine, St. Louis,
MO; 4National Cancer Institute, Bethesda, MD; 5University of Minne-
sota, Minneapolis, MN; 6Chimerix, Inc., Durham, NC
Cytomegalovirus (CMV) infections are associated with signifi-
cant morbidity and mortality in the stem cell transplant setting.
CMX001, a lipid conjugate of cidofovir is administered orally
and circulates as the lipid conjugate in plasma; it is efficiently taken
up by target cells and high concentrations of the active antiviral are
achieved intracellularly. We describe the first clinical experiences
in stem cell transplant patients infected with CMV who received
CMX001. The patients had history of AML (3 patients), refractory
lymphoma, multiple myeloma, and severe aplastic anemia, and
sickle cell anemia. Six of the seven patients had received SCT
and the seventh awaited SCT. Treatment with CMX001 was
